Therapeutic targeting of myeloid-derived suppressor cells.
Myeloid-derived suppressor cells (MDSCs) represent a subset of myeloid cells that expand under pathological conditions, such as cancer development, acute and chronic infections, trauma, bone marrow transplantations, and some autoimmune diseases. MDSCs mediate a negative regulation of the immune response by affecting different T lymphocyte subsets. Potential mechanisms, which underlie this inhibitory activity range from those requiring direct cell-to-cell contact with others, more indirect, and mediated by the modification of the microenvironment. Pharmacological inhibition of MDSC suppressive pathways is a promising strategy to overcome disease-induced immune defects, which might be a key step in enhancing the effectiveness of immune-based therapies.
Ugel
Stefano
S
Department of Oncology and Surgical Science, Via Gattamelata 64, 35128 Padova, Italy.
Delpozzo
Federica
F
Desantis
Giacomo
G
Papalini
Francesca
F
Simonato
Francesca
F
Sonda
Nada
N
Zilio
Serena
S
Bronte
Vincenzo
V
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007155:Immunologic Factors / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D022423:Myeloid Cells / Q000187:drug effects / Q000276:immunology*; D013491:Suppressor Factors, Immunologic / Q000502:physiology*
D007155:Immunologic Factors; D013491:Suppressor Factors, Immunologic